Three-pronged approach required for diplopia

Article

Diplopia is a common presenting complaint that has multiple underlying causes, both neurogenic and myogenic.

The first task is to determine whether the diplopia is monocular or binocular because the underlying causes and treatments are very different. Monocular diplopia usually occurs due to an uncorrected refractive error or corneal disorder that may be treated with refraction. "Other causes can be cataracts, scarring, or a dislocated lens, but monocular diplopia is rarely due to a nerve or muscle abnormality," he said.

Binocular diplopia is the more complex problem. The most common causes are cranial nerve palsy (cranial nerves III, IV, or VI), myasthenia gravis, thyroid-related ophthalmopathy, and orbital tumor.

"Approach the patient by taking a good history, measuring motility by a cover test in the seven positions of gaze, and evaluating associated findings, such as redness, ptosis, proptosis, pupillary abnormalities, and involvement of cranial nerves V and VII," Dr. Mitchell suggested. "Lab tests and imaging studies can help you home in on the right diagnosis."

Ophthalmoscopy is useful for noting any papilledema. Other clinical signs to look for include lid lag, lid retraction, and lid fatigue.

Diagnosing nerve palsies

Cover testing in seven positions of gaze is essential for diagnosing cranial nerve palsy. This test will reveal patterns of muscle weakness that directly correlate with cranial nerves III, IV and VI. Specifically:

Most cranial nerve palsies are ischemic in nature and self-resolve within 3 months. One caution: A third-nerve palsy that presents with pupil dilation and diplopia is a medical emergency, because this usually means an aneurysm at the posterior communicating artery. "These patients should undergo an MRI [magnetic resonance imaging] or MRA [magnetic resonance angiography] study that same day," Dr. Mitchell said.

Cancer or a compressive lesion should always be considered in non-resolving cranial nerve palsy or when two or more nerves are involved.

Myasthenia gravis

Ocular signs are the initial finding in some 75% of myasthenia gravis cases.1 Also, ocular findings are the only signs in more than half the cases of myasthenia gravis.1

"Consider myasthenia gravis in any patient presenting with diplopia, even in those with an isolated cranial nerve palsy pattern," Dr. Mitchell said.

A diurnal variation in diplopia-worsening during the day-is another common manifestation of myasthenia gravis. So, optometrists should question patients about patterns of diplopia.

Laboratory testing and electromyography can confirm the diagnosis of myasthenia gravis. Treatment for this neuromuscular disorder manages the autoimmune response to minimize symptoms, so optometrists should refer these patients to a neurologist.

Recent Videos
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.